Article
SETD2: an epigenetic modifier with tumor suppressor functionality.
Oncotarget - 2 Aug 2016
Li Jun, Duns Gerben, Westers Helga, Sijmons Rolf, van den Berg Anke, Kok Klaas
Abstract excerpt
In the past decade important progress has been made in our understanding of the epigenetic regulatory machinery. It has become clear that genetic aberrations in multiple epigenetic modifier proteins are associated with various types of cancer. Moreover, targeting the epigenome has emerged as a novel tool to treat cancer patients. Recently, the first drugs have been reported that specifically target SETD2-negative...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.